Skip to main content
SpringerLink
Log in
Book cover

Neuro-ophthalmic Disorders pp 1–15Cite as

Emerging Trends in Optic Neuritis and Associated Demyelinating Diseases

  • Chapter
  • First Online:

  • 611 Accesses

Part of the book series: Current Practices in Ophthalmology ((CUPROP))

Abstract

Optic neuritis is a disease of extreme importance from the point of view of neuro-ophthalmologists. As a disease entity, it includes a spectrum ranging from the typical demyelinating isolated optic neuritis to that associated with systemic diseases such as multiple sclerosis and neuromyelitis optica and other atypical forms. This chapter discusses the clinical manifestations of the disease—the signs, symptoms, and the pertinent examination findings; it also highlights the required investigations and the differential diagnoses. The initial management of acute optic neuritis is described and also details about the prognosis in terms of the risk of developing the major associated neurological diseases, i.e., multiple sclerosis and neuromyelitis optica is discussed in detail. The long-term management strategies are also explained.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326:581–8. https://doi.org/10.1056/NEJM199202273260901.

    Article  CAS  PubMed  Google Scholar 

  2. Miller NR, Subramanian PS, Patel VR. Optic neuritis. In: Walsh and Hoyt’s clinical neuro-ophthalmology: the essentials. Philadelphia: Wolters Kluwer; 2016. p. 130–44.

    Google Scholar 

  3. Waldman AT, Stull LB, Galetta SL, et al. Pediatric optic neuritis and risk of multiple sclerosis: meta-analysis of observational studies. J AAPOS. 2011;15:441–6. https://doi.org/10.1016/j.jaapos.2011.05.020.

    Article  PubMed  Google Scholar 

  4. Rodriguez M, Siva A, Cross SA, et al. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology. 1995;45:244–50.

    Article  CAS  PubMed  Google Scholar 

  5. Lau PPK, Yau GSK, Lee JWY, et al. Optic neuritis in Hong Kong: a 1-year follow-up study. Int Ophthalmol. 2014;35(3):303–10. https://doi.org/10.1007/s10792-014-9945-5.

    Article  PubMed  Google Scholar 

  6. Saxena R, Phuljhele S, Menon V, et al. Clinical profile and short-term outcomes of optic neuritis patients in India. Indian J Ophthalmol. 2014;62:265–7. https://doi.org/10.4103/0301-4738.121131.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Messenger W, Hildebrandt L, Mackensen F, et al. Characterisation of uveitis in association with multiple sclerosis. Br J Ophthalmol. 2015;99:205–9. https://doi.org/10.1136/bjophthalmol-2014-305518.

    Article  PubMed  Google Scholar 

  8. Keltner JL, Johnson CA, Cello KE, et al. Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years. Arch Ophthalmol. 2010;128:330–7. https://doi.org/10.1001/archophthalmol.2010.16.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Nevalainen J, Krapp E, Paetzold J, et al. Visual field defects in acute optic neuritis--distribution of different types of defect pattern, assessed with threshold-related supraliminal perimetry, ensuring high spatial resolution. Graefes Arch Clin Exp Ophthalmol. 2008;246:599–607. https://doi.org/10.1007/s00417-007-0722-2.

    Article  CAS  PubMed  Google Scholar 

  10. Rizzo JF, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2002;109:1679–84.

    Article  PubMed  Google Scholar 

  11. Vaphiades MS. Disk edema and cranial MRI optic nerve enhancement: how long is too long? Surv Ophthalmol. 2001;46:56–8.

    Article  CAS  PubMed  Google Scholar 

  12. Beck RW, Trobe JD. What we have learned from the optic neuritis treatment trial. Ophthalmology. 1995;102:1504–8. https://doi.org/10.1016/S0161-6420(95)30839-1.

    Article  CAS  PubMed  Google Scholar 

  13. Mancuso JD, Mody RM, Olsen CH, et al. The long-term effect of Bacille Calmette-Guérin vaccination on tuberculin skin testing: a 55-year follow-up study. Chest. 2017;152(2):282–94. https://doi.org/10.1016/j.chest.2017.01.001.

    Article  PubMed  Google Scholar 

  14. Frohman EM, Shah A, Eggenberger E, et al. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics. 2007;4:618–26. https://doi.org/10.1016/j.nurt.2007.07.008.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115:1079–1082.e5. https://doi.org/10.1016/j.ophtha.2007.08.004.

    Article  Google Scholar 

  16. Filippi M, Rocca MA, Ciccarelli O, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15:292–303. https://doi.org/10.1016/S1474-4422(15)00393-2.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65:727–32. https://doi.org/10.1001/archneur.65.6.727.

    Article  Google Scholar 

  18. Kawasaki A, Purvin VA. Idiopathic chiasmal neuritis: clinical features and prognosis. Arch Ophthalmol. 2009;127:76–81. https://doi.org/10.1001/archophthalmol.2008.516.

    Article  PubMed  Google Scholar 

  19. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–89.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–12. https://doi.org/10.1016/S0140-6736(04)17551-X.

    Article  CAS  PubMed  Google Scholar 

  21. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805–15. https://doi.org/10.1016/S1474-4422(07)70216-8.

    Article  CAS  PubMed  Google Scholar 

  22. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70:2197–200. https://doi.org/10.1212/01.wnl.0000303817.82134.da.

    Article  CAS  PubMed  Google Scholar 

  23. Balcer LJ, Galetta SL. OCT and NMO: are there methods to our madness? J Neuroophthalmol. 2013;33:209–12. https://doi.org/10.1097/WNO.0b013e3182a1e6aa.

    Article  PubMed  Google Scholar 

  24. Lange AP, Sadjadi R, Zhu F, et al. Spectral-domain optical coherence tomography of retinal nerve fiber layer thickness in NMO patients. J Neuroophthalmol. 2013;33:213–9. https://doi.org/10.1097/WNO.0b013e31829c510e.

    Article  PubMed  Google Scholar 

  25. Bennett J, de Seze J, Lana-Peixoto M, et al. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler. 2015;21(6):678–88. https://doi.org/10.1177/1352458514567216.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology. 2009;72:1077–82. https://doi.org/10.1212/01.wnl.0000345042.53843.d5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Park K-A, Kim J, Oh SY. Analysis of spectral domain optical coherence tomography measurements in optic neuritis: differences in neuromyelitis optica, multiple sclerosis, isolated optic neuritis and normal healthy controls. Acta Ophthalmol. 2013;92(1):e57–65. https://doi.org/10.1111/aos.12215.

    Article  PubMed  Google Scholar 

  28. Fernandes DB, Raza AS, Nogueira RG, et al. Evaluation of inner retinal layers in patients with multiple sclerosis or neuromyelitis optica using optical coherence tomography. Ophthalmology. 2013;120(2):387–94. https://doi.org/10.1016/j.ophtha.2012.07.066.

    Article  PubMed  Google Scholar 

  29. Ratchford JN, Quigg ME, Conger A, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology. 2009;73:302–8. https://doi.org/10.1212/WNL.0b013e3181af78b8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology. 2009;73:46–52. https://doi.org/10.1212/WNL.0b013e3181aaea32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Khanna S, Sharma A, Huecker J, et al. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol. 2012;32:216–20. https://doi.org/10.1097/WNO.0b013e318254c62d.

    Article  PubMed  Google Scholar 

  32. Storoni M, Davagnanam I, Radon M, et al. Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system. J Neuroophthalmol. 2013;33:123–7. https://doi.org/10.1097/WNO.0b013e318283c3ed.

    Article  PubMed  Google Scholar 

  33. Fernandes DB, Ramos R de IP, Falcochio C, et al. Comparison of visual acuity and automated perimetry findings in patients with neuromyelitis optica or multiple sclerosis after single or multiple attacks of optic neuritis. J Neuroophthalmol. 2012;32:102–6. https://doi.org/10.1097/WNO.0b013e31823a9ebc.

    Article  PubMed  Google Scholar 

  34. Merle H, Olindo S, Jeannin S, et al. Visual field characteristics in neuromyelitis optica in absence of and after one episode of optic neuritis. Clin Ophthalmol. 2013;7:1145. https://doi.org/10.2147/OPTH.S43894.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Zhou H, Zhao S, Yin D, et al. Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages. J Neurol. 2016;263:1382–9. https://doi.org/10.1007/s00415-016-8155-7.

    Article  CAS  PubMed  Google Scholar 

  36. Lin N, Liu Q, Wang X, et al. Role of AQP4 antibody serostatus and its prediction of visual outcome in neuromyelitis optica: a systematic review and meta-analysis. Protein Pept Lett. 2017;24:245–52. https://doi.org/10.2174/0929866524666170110150436.

    Article  CAS  PubMed  Google Scholar 

  37. Brody J, Hellmann MA, Marignier R, et al. Neuromyelitis optica spectrum disorder: disease course and long-term visual outcome. J Neuroophthalmol. 2016;36(4):356–62. https://doi.org/10.1097/WNO.0000000000000403.

    Article  PubMed  Google Scholar 

  38. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343:898–904. https://doi.org/10.1056/NEJM200009283431301.

    Article  CAS  PubMed  Google Scholar 

  39. CHAMPS Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol. 2001;132:463–71.

    Article  Google Scholar 

  40. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242–9. https://doi.org/10.1212/01.wnl.0000237641.33768.8d.

    Article  CAS  PubMed  Google Scholar 

  41. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503–11. https://doi.org/10.1016/S0140-6736(09)61259-9.

    Article  CAS  PubMed  Google Scholar 

  42. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain J Neurol. 2003;126:770–82.

    Article  Google Scholar 

  43. Deryck O, Ketelaer P, Dubois B. Clinical characteristics and long term prognosis in early onset multiple sclerosis. J Neurol. 2006;253:720–3. https://doi.org/10.1007/s00415-006-0095-1.

    Article  PubMed  Google Scholar 

  44. Baghizadeh S, Sahraian MA, Beladimoghadam N. Clinical and demographic factors affecting disease severity in patients with multiple sclerosis. Iran J Neurol. 2013;12:1–8.

    PubMed  PubMed Central  Google Scholar 

  45. Goodin DS, Bates D. Review: treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler. 2009;15:1175–82. https://doi.org/10.1177/1352458509107007.

    Article  CAS  PubMed  Google Scholar 

  46. Iaffaldano P, Viterbo RG, Trojano M. Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients. J Neurol. 2016;263(8):1620–5. https://doi.org/10.1007/s00415-016-8177-1.

    Article  CAS  PubMed  Google Scholar 

  47. Simao LM. Ophthalmologic manifestations commonly misdiagnosed as demyelinating events in multiple sclerosis patients. Curr Opin Ophthalmol. 2010;21:436–41. https://doi.org/10.1097/ICU.0b013e32833eade6.

    Article  PubMed  Google Scholar 

  48. Zarbin MA, Jampol LM, Jager RD, et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013;120:1432–9. https://doi.org/10.1016/j.ophtha.2012.12.040.

    Article  PubMed  Google Scholar 

  49. Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology. 2012;78:672–80. https://doi.org/10.1212/WNL.0b013e318248deea.

    Article  CAS  PubMed  Google Scholar 

  50. Collongues N, Marignier R, Zéphir H, et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology. 2010;74:736–42. https://doi.org/10.1212/WNL.0b013e3181d31e35.

    Article  CAS  PubMed  Google Scholar 

  51. Yanagawa K, Kawachi I, Toyoshima Y, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology. 2009;73:1628–37. https://doi.org/10.1212/WNL.0b013e3181c1deb9.

    Article  CAS  PubMed  Google Scholar 

  52. Bedi GS, Brown AD, Delgado SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011;17:1225–30. https://doi.org/10.1177/1352458511404586.

    Article  CAS  PubMed  Google Scholar 

  53. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65:1443–8. https://doi.org/10.1001/archneur.65.11.noc80069.

    Article  PubMed  Google Scholar 

  54. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77:659–66. https://doi.org/10.1212/WNL.0b013e31822a2780.

    Article  CAS  PubMed  Google Scholar 

  55. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66:1128–33. https://doi.org/10.1001/archneurol.2009.175.

    Article  PubMed  Google Scholar 

  56. Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71:324–30. https://doi.org/10.1001/jamaneurol.2013.5699.

    Article  PubMed  Google Scholar 

  57. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12:554–62. https://doi.org/10.1016/S1474-4422(13)70076-0.

    Article  CAS  PubMed  Google Scholar 

  58. Palace J, Leite MI, Nairne A, Vincent A. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. 2010;67:1016–7. https://doi.org/10.1001/archneurol.2010.188.

    Article  PubMed  Google Scholar 

  59. Shimizu J, Hatanaka Y, Hasegawa M, et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010;75:1423–7. https://doi.org/10.1212/WNL.0b013e3181f8832e.

    Article  CAS  PubMed  Google Scholar 

  60. Balcer LJ, Frohman EM. Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity. Neurology. 2010;74(Suppl 3):S16–23. https://doi.org/10.1212/WNL.0b013e3181dbb664.

    Article  PubMed  Google Scholar 

  61. Martínez-Lapiscina EH, Ortiz-Pérez S, Fraga-Pumar E, et al. Colour vision impairment is associated with disease severity in multiple sclerosis. Mult Scler. 2014;20:1207–16. https://doi.org/10.1177/1352458513517591.

    Article  PubMed  Google Scholar 

  62. Zhao J, Dave SB, Wang J, Subramanian PS. Clinical color vision testing and correlation with visual function. Am J Ophthalmol. 2015;160:547–552.e1. https://doi.org/10.1016/j.ajo.2015.06.015.

    Article  PubMed  Google Scholar 

  63. Garcia-Martin E, Rodriguez-Mena D, Herrero R, et al. Neuro-ophthalmologic evaluation, quality of life, and functional disability in patients with MS. Neurology. 2013;81:76–83. https://doi.org/10.1212/WNL.0b013e318299ccd9.

    Article  CAS  PubMed  Google Scholar 

  64. Jasse L, Vukusic S, Durand-Dubief F, et al. Persistent visual impairment in multiple sclerosis: prevalence, mechanisms and resulting disability. Mult Scler. 2013;19(12):1618–26. https://doi.org/10.1177/1352458513479840.

    Article  PubMed  Google Scholar 

  65. Dasenbrock HH, Smith SA, Ozturk A, et al. Diffusion tensor imaging of the optic tracts in multiple sclerosis: association with retinal thinning and visual disability. J Neuroimaging. 2011;21:e41–9. https://doi.org/10.1111/j.1552-6569.2010.00468.x.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology. 2006;113:324–32. https://doi.org/10.1016/j.ophtha.2005.10.040.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work is supported in part by a Challenge Grant to the Department of Ophthalmology, University of Colorado, from Research to Prevent Blindness, Inc.

Disclosure

Dr. Subramanian has no relevant financial disclosures.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, USA

    Prem S. Subramanian

Authors
  1. Prem S. Subramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Prem S. Subramanian .

Editor information

Editors and Affiliations

  1. L V Prasad Eye Institute, Hyderabad, India

    Preeti Patil Chhablani

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Subramanian, P.S. (2020). Emerging Trends in Optic Neuritis and Associated Demyelinating Diseases. In: Chhablani, P. (eds) Neuro-ophthalmic Disorders. Current Practices in Ophthalmology. Springer, Singapore. https://doi.org/10.1007/978-981-13-8522-3_1

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-8522-3_1

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-8521-6

  • Online ISBN: 978-981-13-8522-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation